Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran.

[1][2][3]It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.

[2] It's planned to produce one million doses of the vaccine each month as of September 2021.

[4] As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.

[6] 30 (10 μg/200 μL) 30 (20 μg/200 μL) 13 (sentinel) 20,564 (Sinopharm BIBP vaccine) This article about COVID-19 vaccines is a stub.